pemafibrate
Kowa Pharmaceuticals
[]
prominent trial: pemafibrate reduced triglycerides, vldl-c, remnant cholesterol, and apociii by 20 to 30%, pemafibrate did not reduce cv event rates in diabetes, mild-to-moderate hypertriglyceridemia, low hdl-c, and well-controlled ldl-c #aha2022 
Non-Profit Founder/Leader | ?? Doc | Artist | Scientist | Educator | News Anchor https://t.co/usmuA3tKft | RT ? endorse | Disclaimer: https://t.co/bwmE2O3U5W